01877.HK
Shanghai Junshi Biosciences Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 17.31
+0.70%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 17.21
From 52W high−50.43%
Volume2.84M
Market capHKD 17.76B
P/E (TTM)—
P/S (TTM)5.1x
Div yield—
Key dataSep 18, 2026
Open
HKD 17.21
From 52W high
−50.43%
Volume
2.84M
Market cap
HKD 17.76B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−48.5x
P/E (TTM)
—
RSI (14)
43.6
MomentumView details →
1D Return
+0.70%
YTD Return
−18.88%
Similar companies
Latest newsMore news →
Shanghai Junshi Biosciences held an online investor briefing on its 2026 half-year results on September 14, 2026, with CEO Zou Jianjun, independent non-executive director Li Zhongxian, CFO Xu Baohong and board secretary Wang Zhengyu receiving investors.6d agoJunshi Biosciences announced at its 2026 interim results briefing that Phase III clinical trials for its drug candidates JS203 and JS207 are expected to start within 2026.6d agoJunshi Biosciences announced the cancellation of 6.3 million H shares repurchased between May 26 and June 4, 2026, at a price of HK$17.51 per share, reducing total issued shares to 327,888,000.20d ago